{"id":"sorafenib-sora","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Hand-foot skin reaction"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Fatigue"},{"rate":"15-25","effect":"Hypertension"},{"rate":"15-25","effect":"Rash"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Alopecia"}]},"_chembl":null,"_dailymed":{"setId":"b7919013-1511-44f0-a759-3fa78a9fa178","title":"SORAFENIB TOSYLATE (SORAFENIB) TABLET, FILM COATED [MYLAN PHARMACEUTICALS INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sorafenib inhibits multiple serine/threonine and receptor tyrosine kinases, including RAF kinase (involved in the MAPK pathway), VEGFR-2 and VEGFR-3 (which promote tumor angiogenesis), and PDGFR-β (which supports tumor vasculature). By blocking these pathways simultaneously, it reduces both direct tumor cell growth and the formation of new blood vessels that feed tumors.","oneSentence":"Sorafenib is a multi-kinase inhibitor that blocks RAF, VEGFR, and PDGFR signaling to inhibit tumor cell proliferation and angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:55:04.572Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"},{"name":"Renal cell carcinoma"},{"name":"Differentiated thyroid cancer"}]},"trialDetails":[{"nctId":"NCT07264010","phase":"PHASE2, PHASE3","title":"Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-12-01","conditions":"Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD)","enrollment":87},{"nctId":"NCT01518413","phase":"PHASE1","title":"Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors","status":"COMPLETED","sponsor":"HMeany","startDate":"2011-12","conditions":"Rhabdomyosarcoma and Other Soft Tissue Sarcomas, Ewing's Sarcoma Family of Tumors, Osteosarcoma","enrollment":17}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":84,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sorafenib (SORA)","genericName":"Sorafenib (SORA)","companyName":"Nanfang Hospital, Southern Medical University","companyId":"nanfang-hospital-southern-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sorafenib is a small molecule inhibitor of the RAF proto-oncogene serine/threonine-protein kinase. It is used to treat various conditions, including Acute Myeloid Leukaemia (AML), Measurable Residual Disease (MRD), Rhabdomyosarcoma and Other Soft Tissue Sarcomas, Ewing's Sarcoma Family of Tumors, and Osteosarcoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}